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were positively correlated to age (p  0.05). This effect
was caused by slightly rising total treatment costs over
age and a declining number of patients fulfilling the effec-
tiveness criterion.
CONCLUSION: Cost-effectiveness ratios are positively
correlated to age in the treatment of moderate asthmatics.
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OBJECTIVE: To investigate the feasibility of different
methodologies for a prospective matched-pair design study
on the incremental daily cost of disease for patients with
nosocomial pneumonia (NP) from a hospital’s perspective. 
METHOD: Adult patients newly admitted to three ICUs
with 3 days of hospitalization and without preexisting
pneumonia were followed up daily until discharge (maxi-
mum 30 days). Any new onset of NP was registered. Gen-
der, age, diagnosis at admission, underlying disease, surgery,
ward, further diagnosis, Apache II-Score, and Kropec-
Pneumonia-Risc-Score were preselected as matching cri-
teria for controls. Consumed resources were documented
daily. Costs were calculated by two methods: a combined
bottom-up approach (resource consumption of drugs,
blood products, diagnostics, other medical materials) and
top-down approach (proportionate cost based on ac-
counting figures by ward for all other costs). Alterna-
tively, all costs were calculated top-down based on ad-
ministrative data.
RESULTS: In 25 days 112 patients were registered; 50
met all study criteria, of whom 3 developed nosocomial
pneumonia. Matching was possible only on gender, age,
reason for admission (eight categories), ward, hospital
days until onset, immunosuppressive and respiratory sta-
tus. The average incremental daily cost for patients with
NP was DM 440  140%. Both costing methods led to
similar results (2% difference). The first method required
significantly more time for data collection. The sample
size for a study, given that the 95% confidence range of
cost equals the mean of the incremental cost (33%), is 40
patients with NP, plus an adequate number of controls.
CONCLUSION: The approach involving some bottom-
up data is not feasible for a full study. The top-down only
approach more efficiently leads to quite similar results.
For reconfirmation, a larger sample size would be neces-
sary. However, time saved accompanies a loss in preci-
sion. In the future, more wards, with preferably long av-
erage stays, should be included to efficiently document
more cases of nosocomial pneumonia.
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Smoking is a high-risk behavior affecting the health and
economic welfare of a society. Thus it is important to
quantify the economic burden of the negative impact due
to smoking in Germany. Approximately 33.4% of the
male and 20.4% of the female German population are
current smokers.
OBJECTIVE: This study investigates the healthcare costs
of smoking on the six most frequent diseases associated
with the inhalation of tobacco smoke: lung cancer (ICD
162; attributable to smoking, 89%), cancer of the mouth
and larynx (ICD 140–149, 161; 85%), chronic obstruc-
tive pulmonary disease (COPD, ICD 490–491; 73%),
coronary artery disease (ICD 410–414; 35%), stroke
(ICD 434–438; 28%), and atherosclerotic occlusive dis-
ease (ICD 440; 28%).
METHODS: A data search was carried out using several
literature databases including MedLine and DIMDI, as
well as health insurance and Federal Institute of Statistics
databases.
RESULTS: Total smoking-related costs for these diseases
in Germany are 31.4  109 DM, equivalent to 49% of the
overall costs. In detail (1995 figures), smoking-related lung
cancer contributes 4.8  109 DM, cancer of the mouth and
larynx 2.5  109 DM, COPD 11.3  109 DM, coronary
artery disease 8.6  109 DM, stroke 3.1  109 DM, and
atherosclerotic occlusive disease 1.1  109 DM.
CONCLUSION: The conservative calculation of the eco-
nomic impact based on only 6 of more than 25 diseases
known to be associated with smoking results already in a
burden of more than 31 billion DM. Further detailed
analyses are needed to better quantify the health eco-
nomic impact.
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OBJECTIVES: To calculate the costs and cost-effective-
ness of a fixed combination of diclofenac 75 mg 
 miso-
prostol 200 g bid compared with diclofenac 75 mg bid
in preventing gastropathy in Belgium.
METHODS: We developed a new decision-analytical
model comparing diclofenac 
 misoprostol (DM) to di-
clofenac (D), taking into account clinical data on gastrop-
